A revolutionary approach to chimeric antigen receptor (CAR) T-cell therapy, utilizing innovative Split-CAR technology that offers unparalleled versatility and enhanced efficacy. Our proprietary Split-CAR system seamlessly integrates with both allogeneic and autologous T cells, enabling the development of personalized therapies tailored to individual patients.
Elevating CAR T-cell therapy to new heights, our Multi-Target Split-CARs effectively combat multiple tumor targets simultaneously, maximizing therapeutic impact while minimizing tumor escape. This multi-pronged approach ensures comprehensive tumor eradication and enhances treatment outcomes.
Recognizing the potential for CRS, a serious side effect associated with CAR T-cell therapy, we have developed strategies to mitigate its occurrence. Our Split-CAR platform incorporates unique features that minimize CRS, providing patients with a safer and more tolerable treatment experience.
Our Split-CAR technology represents a transformative advance in CAR T-cell therapy, offering a multitude of advantages for patients battling cancer. With its universal applicability, multi-target capabilities, and CRS mitigation strategies, Split-CARs hold immense promise for revolutionizing cancer treatment and improving patient outcomes.
CLICK CAR technology is applicable and adaptable to any type of immunotherapy and is currently being explored for use with NK cells, TILs, dentritic cells…
The CAR of interest is produced as two independent moieties, both fused to a complementary split intein. Upon specific intein reaction, the full length CAR will be constituted, ex vivo or in vivo.